New auxiliary treatment approved for patients with stage IIIA non-small cell lung cancer approved by Junshi Bio Treplymono

Recently, according to relevant news, Junshi bio-Treplymono-approved clinical, for combined chemotherapy in the resectionable phase IIIA non-small cell lung cancer patients of the new auxiliary treatmentAbout Trepri monoantigenTrepri monoantigen is the first domestic PD-1/L1drug(http://approved in China, the first indication approved is melanoma, the product named TuyiJunshi Biological Semi-Annual Report revealed that Trepley mono-anti is currently under going on or will soon carry out a number of clinicaltrials(http://, including second-line nasopharyngeal cancer, second-line urinary disease, first-line nasopharyngeal cancer, first-line EGFR non-mutation (wild type) non-small cells Lung cancer, EGFR-TKI treatment of failed EGFR mutation synty non-small cell lung cancer, hepatocellular carcinoma after surgery assisted therapy, advanced esophageal squamous cancer, first-line melanoma, mucosal melanoma, triynom breast cancer and broad stage small cell lung cancer